đź•’ Created

Novartis stock rose 0.5% as the company secured a licensing agreement with Alteogen to develop subcutaneous medicine versions.

Novartis stock increased by 0.5% late Wednesday as the company entered into an option and licensing pact with South Korea’s Alteogen. The agreement allows Novartis to use Alteogen’s ALT-B4 drug-delivery technology to develop subcutaneous versions of multiple Novartis treatments.

Show the rest of this summary

Subcutaneous delivery involves a shot under the skin, which can replace more complex injection routines or infusions. This deal helped lift broader biotech and healthcare shares. The NYSE Healthcare Index rose 0.8%, and the iShares Biotechnology ETF (IBB) gained 1.4%. While Novartis stock itself saw a moderate gain, the market responded positively to the fact that the ALT-B4 platform can be applied across a Novartis portfolio. This delivery technology can turn multiple established drugs into simpler shots, extending the commercial life of a mature medicine by adding new intellectual property and making products easier for patients and clinics to use.

Sources

Paywall and unreadable sources